U.S. Markets open in 2 hrs 5 mins

Syndax Pharmaceuticals, Inc. (SNDX)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
25.44+0.37 (+1.48%)
At close: 04:00PM EST
26.26 +0.82 (+3.22%)
After hours: 06:50PM EST

Syndax Pharmaceuticals, Inc.

35 Gatehouse Drive
Building D Floor 3
Waltham, MA 02451
United States
781 419 1400

Full Time Employees59

Key Executives

NameTitlePayExercisedYear Born
Mr. Michael A. Metzger M.B.A.CEO & Director899.15kN/A1971
Dr. Briggs W. Morrison M.D.Pres, Head of R&D and Director935.84kN/A1960
Dr. Anjali Ganguli Ph.D.Chief Bus. Officer450.58kN/A1976
Dr. Peter Ordentlich B.Sc., Ph.D.Co-Founder & Chief Scientific OfficerN/AN/A1969
Dr. Richard A. Heyman Ph.D.Co-FounderN/AN/A1957
Dr. Ronald M. Evans Ph.D.Co-Founder, Advisor and Chair of Scientific Advisory BoardN/AN/AN/A
Dr. Michael Downes Ph.D.Co-FounderN/AN/AN/A
Mr. Keith Alan Goldan CPAChief Financial OfficerN/AN/A1971
Mr. Alexander NolteVP & Chief Accounting OfficerN/AN/A1973
Sharon KlahreVP of Investor Relations & CommunicationsN/AN/AN/A
Amounts are as of December 31, 2021 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are SNDX-5613, which is in phase 1/2 clinical trial targeting the binding interaction of Menin with the mixed lineage leukemia 1 protein for the treatment of MLL-rearranged (MLLr) and nucleophosmin 1 mutant acute myeloid leukemia (NPM1c AML); and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD). The company is also developing Entinostat. It also has collaborative research and development agreement with National Cancer Institute; a clinical trial agreement with Eastern Cooperative Oncology Group; and a license agreement with Kyowa Hakko Kirin Co., Ltd. Syndax Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Waltham, Massachusetts.Massachusetts.

Corporate Governance

Syndax Pharmaceuticals, Inc.’s ISS Governance QualityScore as of October 1, 2022 is 8. The pillar scores are Audit: 8; Board: 8; Shareholder Rights: 8; Compensation: 8.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.